No biotech bubble – but can the sector’s rally persist through 2026?
Can biotech sustain its renewed momentum in 2026, or have the biggest near-term opportunities already been...
Read (3m) | 
Listen (13m) | MindMed: Rethinking brain health with psychedelic therapy
CEO Rob Barrow discusses MindMed’s ambitious goals and how the company is helping to forge a new era of...
Funding the future of retinal health with Eyepoint
George Elston, CFO of Eyepoint Pharma, shares insights on retinal disease treatment, covering capital...
How Blackstone Life Sciences is bridging the innovation gap
Blackstone Life Sciences, Paris Panayiotopoulos discusses the role of funding and strategic partnerships in...
Compass trials mark a milestone moment for the psychedelics sector
Compass Pathways' CEO shares his vision for the company and the future of psilocybin therapy for...
Cidara’s pursuit of universal flu protection with a single dose
CEO Jeff Stein discusses Cidara Therapeutics mission and their promising antiviral that could become a new...
Watch (75m) | Pathfinders in Biopharma podcast
Our podcast series explores the fast-moving world of biopharma and what the road ahead looks like for companies and investors in the sector.
More healthcare insights
From biotech breakthroughs to digital transformation, our global healthcare specialists dive deep into the latest trends, innovations, and emerging opportunities.
Stay informed
Get the latest insights from RBC Capital Markets delivered to your inbox.